-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint In Planned Interim Analysis Of Phase 3 Rezilient3 Trial

Reuters·08/12/2026 23:32:06

Please log in to view news